281 related articles for article (PubMed ID: 23846172)
1. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban.
Douxfils J; Tamigniau A; Chatelain B; Chatelain C; Wallemacq P; Dogné JM; Mullier F
Thromb Haemost; 2013 Oct; 110(4):723-31. PubMed ID: 23846172
[TBL] [Abstract][Full Text] [Related]
2. Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban.
Königsbrügge O; Quehenberger P; Belik S; Weigel G; Seger C; Griesmacher A; Pabinger I; Ay C
Ann Hematol; 2015 Sep; 94(9):1463-71. PubMed ID: 26025632
[TBL] [Abstract][Full Text] [Related]
3. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
4. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.
Douxfils J; Dogné JM; Mullier F; Chatelain B; Rönquist-Nii Y; Malmström RE; Hjemdahl P
Thromb Haemost; 2013 Sep; 110(3):543-9. PubMed ID: 23783171
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
Samama MM; Contant G; Spiro TE; Perzborn E; Guinet C; Gourmelin Y; Le Flem L; Rohde G; Martinoli JL;
Thromb Haemost; 2012 Feb; 107(2):379-87. PubMed ID: 22187012
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.
Douxfils J; Mullier F; Loosen C; Chatelain C; Chatelain B; Dogné JM
Thromb Res; 2012 Dec; 130(6):956-66. PubMed ID: 23006523
[TBL] [Abstract][Full Text] [Related]
7. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin.
Mani H; Rohde G; Stratmann G; Hesse C; Herth N; Schwers S; Perzborn E; Lindhoff-Last E
Thromb Haemost; 2012 Jul; 108(1):191-8. PubMed ID: 22534775
[TBL] [Abstract][Full Text] [Related]
8. Assessment of low plasma concentrations of apixaban in the periprocedural setting.
Lessire S; Dincq AS; Siriez R; Pochet L; Sennesael AL; Vornicu O; Hardy M; Deceuninck O; Douxfils J; Mullier F
Int J Lab Hematol; 2020 Aug; 42(4):394-402. PubMed ID: 32297711
[TBL] [Abstract][Full Text] [Related]
9. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
10. Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging.
Lessire S; Douxfils J; Pochet L; Dincq AS; Larock AS; Gourdin M; Dogné JM; Chatelain B; Mullier F
Clin Appl Thromb Hemost; 2018 Jan; 24(1):129-138. PubMed ID: 27811211
[TBL] [Abstract][Full Text] [Related]
11. Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.
Zhang Y; Qian Q; Qian G; Sun G
Br J Biomed Sci; 2016 Jul; 73(3):134-139. PubMed ID: 27400196
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
Gosselin RC; Adcock D; Hawes EM; Francart SJ; Grant RP; Moll S
Thromb Haemost; 2015 Jan; 113(1):77-84. PubMed ID: 25413383
[TBL] [Abstract][Full Text] [Related]
13. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban.
Gosselin RC; Adcock Funk DM; Taylor JM; Francart SJ; Hawes EM; Friedman KD; Moll S
Arch Pathol Lab Med; 2014 Dec; 138(12):1680-4. PubMed ID: 25427046
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
Al-Aieshy F; Malmström RE; Antovic J; Pohanka A; Rönquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
[TBL] [Abstract][Full Text] [Related]
15. Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Rohde G
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Sep; 872(1-2):43-50. PubMed ID: 18675600
[TBL] [Abstract][Full Text] [Related]
16. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
Studt JD; Alberio L; Angelillo-Scherrer A; Asmis LM; Fontana P; Korte W; Mendez A; Schmid P; Stricker H; Tsakiris DA; Wuillemin WA; Nagler M
J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Correlation Between Coagulation Indices and Rivaroxaban Concentrations.
Wu T; Wu S; Li M; Zhang J
Ann Pharmacother; 2024 Jan; 58(1):28-36. PubMed ID: 37125735
[TBL] [Abstract][Full Text] [Related]
18. Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma.
Siriez R; Evrard J; Dogné JM; Pochet L; Bouvy C; Lessire S; Mullier F; Douxfils J
Int J Lab Hematol; 2019 Apr; 41(2):250-261. PubMed ID: 30604921
[TBL] [Abstract][Full Text] [Related]
19. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Barrett YC; Wang Z; Frost C; Shenker A
Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
[TBL] [Abstract][Full Text] [Related]
20. Preliminary report: Measurement of apixaban and rivaroxaban in plasma from bleeding patients.
Jensen KOF; Hansen SH; Goetze JP; Jesting A; Stensballe J; Hansen H
Eur J Haematol; 2017 Nov; 99(5):431-436. PubMed ID: 28833682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
